BRIEF published on 01/20/2025 at 18:05, 1 year 3 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Notification Share Acquisition Atlas Special Opportunities Oxurion Retinal Disease Therapies
BRIEF published on 01/20/2025 at 18:05, 1 year 3 months ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Acquisition D'actions Oxurion Opportunités Spéciales Atlas Avis De Transparence Thérapies Pour Les Maladies De La Rétine
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 3 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV receives transparency notification regarding shares ownership from Atlas Special Opportunities, LLC, crossing the 20% threshold. Company engaged in developing ophthalmic therapies Transparency Notification Ophthalmic Therapies Oxurion NV Shares Ownership Belgian Transparency Legislation
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 3 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC over aankoop aandelen, voldoet aan Belgische transparantiewetgeving. Oogheelkundig bedrijf gevestigd in Leuven, België Transparantiekennisgeving Oxurion NV Biofarmaceutisch Netvliesaandoeningen Belgische Transparantiewetgeving
BRIEF published on 01/14/2025 at 18:05, 1 year 3 months ago Oxurion reçoit une mise à jour de transparence d'Atlas Special Opportunities LLC Actions Atlas Transparence Biopharmaceutique Oxurion
BRIEF published on 01/14/2025 at 18:05, 1 year 3 months ago Oxurion Receives Transparency Update from Atlas Special Opportunities LLC Actions Transparency Atlas Biopharmaceutical Oxurion
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 3 months ago Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC wegens verkoop van aandelen. Leuven biofarmaceutisch bedrijf actief in oftalmologische therapieën Transparantiekennisgeving Oxurion NV Biofarmaceutisch Oftalmologische Therapieën België
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 3 months ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC Oxurion NV announces receiving an amended transparency notification regarding share ownership by Atlas Special Opportunities, LLC, crossing under the 3% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Retinal Disease
BRIEF published on 01/13/2025 at 18:05, 1 year 3 months ago Oxurion Updates Voting Rights Following Convertible Bond Conversion Voting Rights Convertible Bonds Capital Increase Market Opportunities Oxurion
BRIEF published on 01/13/2025 at 18:05, 1 year 3 months ago Oxurion met à jour ses droits de vote suite à la conversion des obligations convertibles Obligations Convertibles Augmentation De Capital Droit De Vote Opportunités De Marché Oxurion
Published on 05/08/2026 at 00:00, 11 minutes ago Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 41 minutes ago Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 22:05, 2 hours 6 minutes ago MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications
Published on 05/07/2026 at 22:05, 2 hours 6 minutes ago Innodata Reports Record First Quarter 2026 Results
Published on 05/07/2026 at 23:23, 47 minutes ago H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness
Published on 05/07/2026 at 23:14, 56 minutes ago EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved
Published on 05/07/2026 at 22:05, 2 hours 5 minutes ago Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 3 hours 28 minutes ago RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 5 hours 25 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/07/2026 at 19:15, 4 hours 56 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 4 hours 56 minutes ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 5 hours 5 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 5 hours 5 minutes ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 5 hours 11 minutes ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
